Definition
- Essential:
- Cerebellar localization AND
- Oligodendroglioma-like monomorphic cells associated with focal lipoma-like changes AND
- Synaptophysin expression AND (for unresolved lesions)
- Methylation profile of cerebellar liponeurocytoma
- Desirable:
- Adult patient Focal GFAP immunoreactivity absence of histological features of malignancy
WHO grading
- Grade 2
- Time to clinical progression is often long (mean: 6.5 years)
Number
- Mean age 50yrs
- Male: female 1:1
- 40 cases published
Clinical features
- Obstructive HCP: H/A
- Cerebellar signs, including ataxia and disturbed gait, are also common
Localisation
- Post fossa
- Cerebellar hemispheres
- Other paramedian region or vermis
- Extend to the cerebellopontine angle or fourth ventricle
Origin
- Cerebellar progenitors, which are distinct from cerebellar granule progenitors
- Not a variant of medulloblastoma
Radiology
CT
- Tumour is variably isodense or hypodense, with focal areas of marked hypoattenuation corresponding to fat density
MRI
- T1: Iso/hypointense with patchy areas of hyperintensity corresponding to regions of high lipid content
- T1+C: Heterogenous enhancement
- T2: tumour is slightly hyperintense to the adjacent brain, with focal areas of marked hyperintensity.
- Little to no oedema
A, T1-weighted MRI (with gadolinium) of a recurrent liponeurocytoma, presenting as an irregular, strongly enhancing lesion in the right cerebellar hemisphere.
B, Axial T1-weighted MRI after gadolinium administration shows areas of prominent hypointense signal within a well-demarcated isodense tumour
Histopathology
- Macroscopic
- Microscopic
- Composed of small neurocytic cells and lipoma-like lipid-laden cells which represent neuroepithelial cells with abundant cytoplasmic lipid
- Features of anaplasia such as nuclear atypia, necrosis, and microvascular proliferation are typically absent in primary lesions, but may be found in recurrent tumours
- Immunophenotype
- Synaptophysin: positive
- Neurone-specific enolase: positive
- MAP2: positive
- GFAP: positive
- Ki67<3% but can be as high as 6%
Genetic profile
- BRAF and IDH mutations were absent
- Losses of chromosomes 14 and 2p
Management
- Surgery is considered the treatment of choice
- No real role for radiotherapy
Prognosis
- Chakraborti et al., 2011
- 5 yrs. survival rate of only 48%
- Recurrence and radioresistance can occur
Differential diagnosis
Features | Cerebellar liponeurocytoma | Medulloblastoma |
Isochromosome 17q mutations of PTCH1, CTNNB1, and APC | Absent | Present |
TP53 missense mutations | Low rate | Higher rate |
Loss of chromosomes 14 and 2p | Present | Absent |